Table 1.
Demographic, clinical, and oncological data of enrolled patients.
| Variable | Patients | Controls | p Value |
|---|---|---|---|
| n = 44 | n = 44 | ||
| Age (years) mean (SD); median (range) | 61.3 (10.7); 61 (55.5–68.5) | 59.5 (9.8); 60 (50–66) | 0.77 |
| Weight (kg) mean (SD); median (range) | 65.4 (9.8); 64 (60.5–69) | 66.6 (9.5); 65 (58–68) | 0.88 |
| BMI (kg/m2) mean (SD); median (range) | 25.6 (5.0); 24 (19–45) | 24.5 (4.8); 24 (18–42) | 0.87 |
| 18–25 | 28 (63.6%) | 30 (68.2%) | |
| 25–30 | 11 (25%) | 10 (22.7%) | |
| >30 | 5 (11.4%) | 4 (9.1%) | |
| Comorbidities | 33 (75%) | 28 (63.6%) | 0.25 |
| Thyroid disorder | 16 (36.4%) | 14 (31.8%) | |
| Cardiovascular disease | 10 (22.7%) | 6 (13.6%) | |
| Respiratory disease | 3 (6.8%) | 4 (9.1%) | |
| Others | 5 (11.4%) | 4 (9.1%) | |
| Type of cancer | |||
| Ovarian | 28 (63.6%) | ||
| Endometrial | 9 (20.4%) | ||
| Cervical | 7 (16%) | ||
| FIGO stage | |||
| I | 12 (27.3%) | ||
| II | 8 (18.2%) | ||
| III | 20 (45.5%) | ||
| IV | 4 (9.1%) | ||
| Chemotherapy | |||
| In progress | 30 (68.2%) | ||
| Within 6 months | 14 (31.8%) | ||
| Progressive disease at the time of vaccination | 23 (52.3%) |
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics.